Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress

Why is Home Depot acquiring GMS for $5 billion? How will Netflix's NASA streaming deal impact viewership? What caused Apple to accuse an engineer of stealing secrets? Why is Trump pressuring the Fed to cut interest rates? How is Meta’s AI hiring spree affecting its stock? What are the effects of Canada scrapping its tech tax? Why did JetBlue cancel major winter flights from New York?

Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress

benzinga.com/analyst-stock-ratings/initiation/25/06/46177255/aardvarks-hunger-suppressing-drug-promises-weight-loss-without-gi-distress

HC Wainwright initiated coverage on Aardvark Therapeutics, Inc. (NASDAQ:AARD) on Monday with a Buy rating and a price forecast of $40.
In February, Aardvark Therapeutics, Inc. (NASDAQ:AARD) priced an initial public offering of 5.9 million at $16 per share, with approximately $94.2…

This story appeared on benzinga.com, 2025-06-30 18:06:53.